Friday, February 14, 2025
spot_imgspot_img

Top 5 This Week

spot_imgspot_img

Related Posts

New medication aims to increase accessibility of treatment for one type of multiple sclerosis


The FDA has approved a new treatment for people suffering from multiple sclerosis that is quicker and easier to administer than previous options. Ocrevus Zunovo is a new version of the drug Ocrevus, which is commonly used to treat primary progressive MS but can take up to four hours to receive intravenously. The new treatment is injected under the skin with a small needle and only takes around 30 minutes to administer, making it much more convenient for patients.

Dr. Robert Shin, director of the Multiple Sclerosis and Clinical Neuroimmunology Division at UVA Health, emphasized the importance of this new treatment for patients who do not have the time to spend hours in an infusion chair. The quicker administration also opens up the possibility for patients in rural areas to receive the medication during regular neurologist checkups, saving them long travel times to infusion centers.

Multiple sclerosis is a potentially disabling disease that occurs when immune system cells attack nerve fibers. The goal of treatment is to slow or stop the progression of the disease, and medications like Ocrevus Zunovo target B-cells that play a key role in MS attacks. The new treatment is also effective in treating relapsing-remitting MS, where attacks are followed by periods of recovery.

Overall, this new treatment option provides hope for people suffering from multiple sclerosis, offering a more efficient and convenient way to receive the necessary medication. Patients and healthcare providers are excited about the potential impact of Ocrevus Zunovo in improving the lives of those with this challenging condition.

Source
Photo credit wtop.com

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Popular Articles